Summary
Definition
History and exam
Key diagnostic factors
- presence of risk factors
- major depressive episode(s)
- episode(s) of mania
- episode(s) of hypomania
- inflated self-esteem or grandiosity
- decreased need for sleep
- more talkative than usual, or feels pressure to keep talking
- flight of ideas, or subjective experience that thoughts are racing
- distractibility
- increase in goal-directed activity or psychomotor agitation
- excessive involvement in pleasurable activities that have a high potential for adverse consequences
- functional impairment
- no substance misuse
- no underlying medical cause
- not due to somatic antidepressant treatment or other prescribed medication
Risk factors
- family history of bipolar disorder or schizophrenia
- onset of mood disorder prior to 20 years of age
- adverse life events
- childhood trauma and/or adversity
- previous history of depression
- lifetime history of a substance use disorder
- presence of an anxiety disorder
- obesity
- cardiovascular disease
Diagnostic investigations
1st investigations to order
- Primary Care Evaluation of Mental Disorders (PRIME-MD)
- Patient Health Questionnaire (PHQ-9)
- Rapid Mood Screener (RMS)
- Mood Disorder Questionnaire (MDQ)
- Bipolarity Index
- Young Mania Rating Scale (YMRS)
- FBC
- thyroid function tests
- serum vitamin D
- toxicology screen
Treatment algorithm
Contributors
Authors
Adrian Preda, MD
Professor of Clinical Psychiatry
University of California, Irvine
Irvine
CA
Disclosures
AP has been compensated as an expert consultant by GLG, Atheneum, Guidepoint, and as the Editor-in-Chief of Psychiatric News.
Acknowledgements
Dr Adrian Preda would like to gratefully acknowledge Dr Sudhakar Selvaraj, Dr Prashant Gajwani, and Dr David J. Muzina, previous contributors to this topic.
Disclosures
SS has received speaking honoraria from Global Medical Education and honoraria from the British Medical Journal Publishing Group; owns convertible shares at Flow MedTech, Inc (a medical device start-up company); and has been involved in a treatment-resistant depression clinical trial and received research support from COMPASS pathways (a mental healthcare company). PG has served on the speakers' bureau for Merck and Sunovion. DJM is an author of a number of references cited in this topic; has previously received honoraria for research support from Repligen Co; has previously received honoraria as a speaker and/or advisor from AstraZeneca, Pfizer, BMS, Wyeth, Sepracor, and GSK; and is a full-time employee of Medco.
Peer reviewers
Stuart Watson, MD, MRCPsych, MBBS
Clinical Senior Lecturer
Newcastle University
Newcastle
UK
Disclosures
SW declares that he has no competing interests.
Roger McIntyre, MD
Head
Mood Disorders Psychopharmacology Unit
University Health Network
Associate Professor of Psychiatry and Pharmacology
University of Toronto
Ontario
Canada
Disclosures
RM has received research funds from Stanley Medical Research Institute and National Alliance for Research on Schizophrenia and Depression (NARSAD). RM is on the advisory boards for AstraZeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline Janssen-Ortho, Solvay/Wyeth, Eli Lilly, Organon, Lundbeck, Biovail, Pfizer, Shire, and Schering-Plough. RM is on the speakers' bureau for Janssen-Ortho, AstraZeneca, Eli Lilly, Lundbeck, Biovail, and Wyeth. RM has received research grants from Eli Lilly, Janssen-Ortho, and Shire.
Jan Scott, MBBS
Professor of Psychological Medicine
University of Newcastle
Honorary Professor
Psychological Treatments Research
Institute of Psychiatry
London
University Department of Psychiatry
Royal Victoria Infirmary
Newcastle upon Tyne
UK
Disclosures
JS has received remuneration for attending advisory boards for AstraZeneca, BSM-Otsuka, Eli Lilly, GSK, and Sanofi-Aventis.
Use of this content is subject to our disclaimer